Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY – Get Free Report) was the recipient of a significant decrease in short interest in September. As of September 30th, there was short interest totaling 39,624 shares, a decrease of 64.6% from the September 15th total of 111,907 shares. Based on an average trading volume of 168,560 shares, the days-to-cover ratio is presently 0.2 days.
Ono Pharmaceutical Stock Up 0.8%
Shares of Ono Pharmaceutical stock opened at $4.76 on Wednesday. The company has a 50 day moving average price of $5.02 and a 200 day moving average price of $4.98. Ono Pharmaceutical has a 52 week low of $3.81 and a 52 week high of $5.75.
About Ono Pharmaceutical
Ono Pharmaceutical Co, Ltd. is a Japan-based, research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Its activities focus primarily on areas of high unmet medical need, including oncology, immunology, neurology and other specialty-care fields.
The company’s best-known product is Opdivo (nivolumab), an immune checkpoint inhibitor used in the treatment of multiple cancers. Ono has also developed or commercialized other specialty medicines, including treatments for cancer and immune-related conditions, through internal research and collaborations with pharmaceutical companies in Japan and overseas.
Ono Pharmaceutical traces its origins to 1717, when it began as a drug wholesaler in Osaka, and was incorporated in its modern corporate form in 1947.
See Also
- Five stocks we like better than Ono Pharmaceutical
- Albertsons Is Betting on a Turnaround—But Will It Pay Off?
- Venezuela’s Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit
- PepsiCo’s Earnings Beat Masks a Bigger Problem With Its North American Business
- Tax Credit Turmoil: Why Enphase and SolarEdge Face a Tough Road
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
